Canaccord Genuity Downgrades Entellus Medical (ENTL) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
- Oil prices gain on attacks in Saudi Arabia, Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
Tweet
Share
E-mailGet Alerts ENTL Hot Sheet
Price: $8.19 -10.39%
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 12 | New: 90
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 12 | New: 90
Join SI Premium – FREE
Canaccord Genuity downgraded Entellus Medical (NASDAQ: ENTL) from Buy to Hold with a price target of $18.00 (from $22.00).
For an analyst ratings summary and ratings history on Entellus Medical click here. For more ratings news on Entellus Medical click here.
Shares of Entellus Medical closed at $15.80 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Downgrades Albertsons Companies Inc. (ACI) to Underperform
- Barclays Downgrades NetApp (NTAP) to Equalweight
- JPMorgan Downgrades Bruker (BRKR) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
